Clevidipine Butyrate (CAS 167221-71-8) is distinguished by its unique pharmacological profile, making it a highly effective agent for blood pressure management. This profile, characterized by rapid metabolism and arterial selectivity, is crucial for its clinical applications. NINGBO INNO PHARMCHEM CO.,LTD. is a leading clevidipine butyrate manufacturer that provides this essential compound.

As a dihydropyridine calcium channel blocker, Clevidipine Butyrate functions by inhibiting the influx of calcium ions into vascular smooth muscle cells. This action leads to vasodilation, a decrease in systemic vascular resistance, and consequently, a reduction in blood pressure. What sets it apart is its remarkable arterial selectivity; it primarily affects peripheral arteries, with minimal impact on the heart muscle itself. This means it lowers blood pressure without causing significant negative inotropic effects or slowing cardiac conduction, which is a critical safety feature.

The metabolism of Clevidipine Butyrate is another key aspect of its pharmacological profile. It is rapidly hydrolyzed by plasma and tissue esterases, resulting in inactive metabolites that are primarily excreted through the kidneys and feces. This rapid breakdown means it has a very short half-life, typically around one minute. This swift inactivation is advantageous as it allows for very precise titration of blood pressure, meaning clinicians can quickly adjust the infusion rate to achieve the desired blood pressure target and minimize risks associated with prolonged or excessive hypotension. This makes it an ideal API for pharmaceutical development.

For entities looking to order clevidipine butyrate, NINGBO INNO PHARMCHEM CO.,LTD. stands as a reliable clevidipine butyrate distributor. Their commitment to delivering high-quality APIs ensures that the therapeutic benefits of Clevidipine Butyrate can be fully realized in final drug products. Understanding the pharmacological nuances of this compound is key for its effective utilization in treating hypertension.

In summary, the pharmacological profile of Clevidipine Butyrate—its arterial selectivity and rapid esterase-mediated metabolism—makes it an exceptionally valuable API for targeted blood pressure control. NINGBO INNO PHARMCHEM CO.,LTD. plays a vital role in making this advanced pharmaceutical intermediate accessible to the global market.